FIELD: medicine, immunology. SUBSTANCE: invention relates to application of Mycobacterium vaccae for feedback inhibition regulation of Th2-activity of immune system. Method involves application of killed cells of Mycobacterium vaccae or their derivatives no containing any antigen, immunogen or allergen and no relating to M. vaccae for treatment of disorder that is characterized by stimulation of Th2-activity of immune system by decrease of Th2-activity being without stimulation of Th1-activity of immune system, namely, for treatment of disorders associated with chronic fatigue syndrome, Persian Gulf war syndrome or total allergy syndrome. The advantage of invention involves the shift of patient immune system from Th1-activity to Th2-activity using the preparation without "foreign" antigen or immunogen. EFFECT: valuable properties of preparation. 9 cl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION, STIMULATING IMMUNE RESPONSE, WHICH CONTAINS NANOPARTICLES BASED ON COPOLYMER OF METHYLVINYL ETHER OF MALEIC ANHYDRIDE | 2005 |
|
RU2379028C2 |
| METHOD FOR PRODUCING POLARIZED LYMPHOCYTES FOR MODELING Th2-INDUCED EDEMA | 2006 |
|
RU2318525C1 |
| DRUG OF HUMIC NATURE, WHICH HAS AN IMMUNOMODULATORY EFFECT | 2022 |
|
RU2783772C1 |
| AGENT BASED ON WATER-SOLUBLE VEGETABLE POLYSACCHARIDES, HAVING ANTIALLERGIC ACTIVITY | 2023 |
|
RU2823873C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ATTENUATED Streptococcus pneumoniae STRAINS, AND ITS APPLICATION | 2018 |
|
RU2772131C2 |
| COMPLEX CONTAINING AN OLIGONUCLEOTIDE, HAVING IMMUNOSTIMULATING ACTIVITY, AND ITS APPLICATION | 2014 |
|
RU2723943C2 |
| MUCOSAL INDUCTION OF ANTIGEN TOLERANCE | 2006 |
|
RU2420569C2 |
| BIOLOGICAL MATERIALS AND THEIR USE | 2009 |
|
RU2508296C2 |
| COMPOSITION CONTAINING Actinidia AND METHODS OF THEIR APPLICATION | 2006 |
|
RU2423139C2 |
| ENHANCING IMMUNE RESPONSE AND TARGET FOCUS BY ANTIGENS AND/OR DRUG | 2008 |
|
RU2548685C2 |
